Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group.

Abstract

PURPOSE:

The response to topiramate (TPM) as long-term adjunctive therapy was evaluated in patients with Lennox-Gastaut syndrome (LGS) in a long-term, open-label extension to a double-blind, placebo-controlled trial.

METHODS:

In 97 patients with LGS (mean age, 11 years), dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted to optimal clinical response (mean TPM dosage, 10 mg/kg/day).

RESULTS:

For those patients who had completed 6 months of TPM therapy, drop attacks were reduced > or =50% in 55% of patients; 15% of patients had no drop attacks for > or =6 months at the last visit. After treatment up to 3+ years, 71% of patients who started open-label TPM were continuing therapy at the last visit.

CONCLUSIONS:

During long-term therapy, TPM is effective and well tolerated in controlling the treatment-resistant drop attacks and seizures associated with LGS.

• Authors: T A Glauser, P M Levisohn, F Ritter, R C Sachdeo
• Journal: Epilepsia (Epilepsia) Vol. 41 Issue S1 Pg. 86-90 ( 2000) ISSN: 0013-9580 [Print] United States
• PMID: 10768308 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Anticonvulsants
• Placebos
• Topiramate
• Fructose

Topics

• Adolescent
• Adult
• Anticonvulsants (therapeutic use)
• Child
• Child, Preschool
• Double-Blind Method
• Drug Administration Schedule
• Drug Therapy, Combination
• Epilepsy (drug therapy)
• Female
• Fructose (analogs & derivatives, therapeutic use)
• Humans
• Male
• Placebos
• Topiramate
• Treatment Outcome